News & Trends - MedTech & Diagnostics
J&J led largest medtech M&A in 2022
MedTech News: Johnson & Johnson’s $17bn acquisition accounted for 42% of medtech M&A spend last year.
Abiomed is now part of Johnson & Johnson and will operate as a standalone business within Johnson & Johnson’s MedTech segment. The acquisition adds heart recovery solutions to complement the company’s Biosense Webster electrophysiology business, supporting the company’s expansion in high-growth markets.
The size and the target of this deal caught the company “off guard”. However, the organisation believes Abiomed is a “high-quality target and fits JNJ’s businesses and company culture well”.
J&J said the acquisition is expected to be slightly dilutive to earnings per share in the first year, then adding $0.05 per share in 2024 and increasingly accretive thereafter.
Interestingly, J&J’s Abiomed takeout was the second-largest in the overall life sciences sector, behind only Amgen’s $28bn acquisition of Horizon, which specialises in medicines for rare and autoimmune diseases.
In comparison, the largest deal Medtronic closed last year involved the sinusitis specialist Intersect ENT at $1.2bn.
One deal is already on the books for 2023 with Thermo Fisher’s £2.3bn ($2.8bn) purchase of The Binding Site earlier this month.
Other big groups that have expressed an interest in buying include Abbott and Medtronic, although they are mostly focused on sub-$1bn tuck-in deals.
In reimagining healthcare, Health Industry HubTM is the ONLY one-stop-hub uniting the diversity of Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change. The exclusive leadership and influencer podcasts and vodcasts offer unparalleled insights and add immense value to our breaking news coverage.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
Digital & Innovation
AI partnership to propel launch of National Lung Cancer Screening Programme
Digital & Innovation: Starting July 2025, the Australian Government will fund the National Lung Cancer Screening Programme (NLCSP), a crucial […]
MoreNews & Trends - Pharmaceuticals
Australian patient groups join Asia-Pacific Heart Summit in urgent call as CVD claims 19 lives every minute
Pharma News: The inaugural Asia-Pacific Heart Summit united over 100 delegates from across the region, including Australia’s hearts4heart and Heart […]
MoreNews & Trends - Pharmaceuticals
Genomic-led cancer care: Unlocking truly personalised treatment for leukaemia patients
Pharma News: A new project has given researchers insight to better predict outcomes and tailor treatment for young adults living […]
MoreNews & Trends - MedTech & Diagnostics
MTAA launches Australian-first medtech regulatory community
MedTech & Diagnostics News: The Medical Technology Association of Australia (MTAA) has today launched the nation’s first medtech regulatory community, […]
More